# BRAF V600E (and V600K)

Source: https://onco.cc/biomarkers/braf-v600e/  
OnCo record `braf-v600e` (Biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

V600E is the BRAF change that drives half of melanomas and many thyroid, bowel, lung and brain tumours. BRAF plus MEK inhibitors are approved for it in melanoma, lung, thyroid and, tumour-agnostically, any solid tumour; in bowel cancer it is treated with encorafenib and cetuximab.

## Summary

The c.1799T>A (V600E) substitution, and the rarer V600K, are class I BRAF mutations that signal as monomers and respond to BRAF inhibitors. Dabrafenib and vemurafenib are labelled for BRAF V600E melanoma; dabrafenib with trametinib for V600E or V600K melanoma, V600E NSCLC, anaplastic thyroid cancer, paediatric low-grade glioma and V600E solid tumours (tumour-agnostic, 2022); encorafenib with binimetinib for V600E or V600K melanoma and V600E NSCLC, and with cetuximab for V600E colorectal cancer. Companion diagnostics on the FDA list include the cobas 4800 BRAF V600, THxID BRAF, therascreen BRAF V600E, FoundationOne CDx and Liquid CDx, Oncomine Dx Target Test, Guardant360 CDx and Caris MI Cancer Seek. Labels warn the drugs are not for BRAF wild-type tumours.

## Fields

- Kind: Biomarker
- Last checked: 2026-09-23
- Also known as: BRAF V600E; V600E; BRAF V600; BRAF V600K; BRAF-mutant; BRAF class I mutation; BRAF V600E-mutant
- Tags: biomarker; braf

## Sources

- Tafinlar prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea
- BRAFTOVI prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c

## Connected records

- biomarkers: [BRAF class II and class III mutations (non-V600)](https://onco.cc/biomarkers/braf-class-ii-iii/), [BRAF fusion or rearrangement](https://onco.cc/biomarkers/braf-fusion/), [KRAS G12C](https://onco.cc/biomarkers/kras-g12c/)
- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Anaplastic thyroid cancer](https://onco.cc/cancers/anaplastic-thyroid-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Paediatric low-grade glioma](https://onco.cc/cancers/paediatric-low-grade-glioma/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- drugs: [Binimetinib](https://onco.cc/drugs/binimetinib/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Cobimetinib](https://onco.cc/drugs/cobimetinib/), [Dabrafenib](https://onco.cc/drugs/dabrafenib/), [Dabrafenib + trametinib](https://onco.cc/drugs/dabrafenib-trametinib/), [Encorafenib](https://onco.cc/drugs/encorafenib/), [therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)](https://onco.cc/drugs/therascreen-cdx/), [Trametinib](https://onco.cc/drugs/trametinib/), [Vemurafenib](https://onco.cc/drugs/vemurafenib/)
- terms: [BRAF V600E mutation](https://onco.cc/terms/braf-v600-mutation/), [Next-generation sequencing (NGS)](https://onco.cc/terms/ngs/), [Tumour-agnostic (tissue-agnostic) approval](https://onco.cc/terms/tumour-agnostic/)
- targets: [BRAF](https://onco.cc/targets/braf/)

---
JSON: https://onco.cc/api/v1/entities/braf-v600e.json